Jan 10, 2024 / 11:00PM GMT
Brian Cheng JPMorgan-Analyst
Good afternoon and thanks for joining us for another session at the 42nd JPMorgan Healthcare Conference. I'm Brian Cheng. I'm one of the senior biotech analysts here. On stage, we have iTeos team. I'll pass the mic to iTeos for a short presentation, followed by a live audience Q&A. If you're joining us live, you can submit a question for the team through our conference portal. iTeos, the stage is yours. Michel?
Michel Detheux iTeos Therapeutics - Inc. - President & CEO
Thank you very much. Good afternoon, everyone, and welcome. I would like to thank you, JPMorgan, for hosting the conference and Brian for inviting us.
Before to start, I would like to spend a few minutes to describe what is iTeos. For the last decade, we have built an incredible expertise in tumor immunology that allow us to go above and beyond to understand how to create differentiated therapies to help people living with cancer. Today, we are very excited to start 2024 because we are into an incredible position with most milestone-driven year
Iteos Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers